Exagen Inc . (NASDAQ:) stock has reached a new 52-week high, touching $4.97 in recent trading. According to InvestingPro data, the company maintains a “GOOD” overall financial health score, with analysts setting price targets between $5 and $8. This milestone reflects a significant turnaround for the company, with the stock price soaring over the past year. Investors have shown increasing confidence in Exagen, as evidenced by the impressive 154.82% return over the past twelve months, including a notable 109.41% gain in just the last six months. The company’s market capitalization now stands at $85.26 million, though InvestingPro analysis indicates the stock is trading near its Fair Value. The company’s recent performance has attracted attention from both industry analysts and investors, who are closely monitoring its growth trajectory and future potential in its respective market….
